Browse the evidence

Genetically proxied GLP-1R-based multi-target agonists (GIPR/GLP-1R, GCGR/GLP-1R, and GCGR/GIPR/GLP-1R) causally reduce the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications, including liver cancer and cardiovascular disease, partly independent of weight loss.

Genetic evidence strongly supports that GLP-1-based therapies (like semaglutide or tirzepatide) reduce the risk of fatty liver disease and its complications (liver cancer, heart disease). This benefit appears to come from improving metabolic health (insulin sensitivity, lipids) directly, not just from losing weight. If you have MASLD, these medications are a promising therapeutic option to discuss with your doctor, regardless of your current weight loss progress.

Discontinuation of semaglutide leads to significant weight regain ('semaglutide rebound'), with studies showing approximately two-thirds of lost weight is regained within one year.

If you stop taking semaglutide, expect to regain about two-thirds of the weight you lost within a year. This 'rebound' effect is common. Plan for sustainable lifestyle changes or discuss long-term management strategies with your doctor before stopping.

Using different prediction equations (Katch-McArdle vs. BIA-derived) to estimate Resting Metabolic Rate (RMR) during weight loss yields significantly different conclusions regarding the presence of metabolic adaptation (MA), with Katch-McArdle suggesting increased metabolic efficiency (increased aRMR) while BIA suggests decreased efficiency (decreased aRMR).

When tracking weight loss, do not rely on a single prediction equation to judge your metabolic health. This study shows that different formulas can contradict each other regarding metabolic adaptation. To minimize this error, prioritize preserving fat-free mass (muscle) through adequate protein intake (approx. 2.0 g/kg FFM as used in the study) and resistance training, as this stabilizes the metabolic rate more reliably than any single calculation method.

Bariatric surgery provides superior, durable weight loss and metabolic improvement compared to non-surgical interventions, including pharmacotherapy.

If you have severe obesity (BMI ≥40, or ≥35 with health issues) and lifestyle changes haven't worked, bariatric surgery is the most effective long-term solution for weight loss and metabolic health. While it has higher upfront costs and risks, it is more cost-effective over time than lifelong medication. Consult a specialist to see if you qualify.

GLP-1 receptor agonists (semaglutide, tirzepatide) and dual agonists produce significant weight loss (15-22.5%) but are associated with lean muscle mass loss and require long-term adherence.

GLP-1 drugs like semaglutide and tirzepatide are highly effective for weight loss (15-22%), but you must take them long-term to maintain results. They can cause muscle loss, so combine them with resistance training and high protein intake. Be aware of GI side effects and contraindications like thyroid cancer history.

Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.

If you have significant excess abdominal skin and metabolic issues (high blood pressure, diabetes, or high cholesterol), do not rush into skin removal surgery. You must first lose weight through diet, medication (like GLP-1s), or bariatric surgery until your weight and metabolic markers are stable for at least 6-12 months. This sequence drastically lowers your risk of infection, blood clots, and poor scarring, and ensures the skin removal looks good long-term.

Metformin, alpha-lipoic acid (ALA), and GLP-1 receptor agonists are effective, complementary pharmacological interventions for managing metabolic syndrome, with metformin serving as the universal first-line treatment due to its safety, low cost, and wide availability.

For patients with Metabolic Syndrome, especially in crisis or resource-limited settings, start with metformin as the primary treatment due to its proven safety, low cost, and wide availability. Add alpha-lipoic acid (ALA) to target oxidative stress and insulin sensitivity, and consider GLP-1 agonists if cardiovascular risk is high and resources allow. Simplify regimens and use telemedicine to support adherence, as stress and disruption are major barriers to care.

The MicroSimulation Core Obesity Model (MS-COM) accurately predicts cardiovascular and mortality outcomes in adults with overweight or obesity, including those with normoglycemia, prediabetes, or type 2 diabetes, supporting its use for evaluating obesity management interventions.

For policymakers and health technology assessment bodies, the MS-COM model provides a reliable tool to evaluate the cost-effectiveness of obesity interventions (like semaglutide 2.4 mg) by accurately predicting long-term cardiovascular and mortality risks in overweight and obese adults, including those with diabetes.

Initiation of GLP-1 receptor agonists in adults with obesity or type 2 diabetes is associated with a substantially reduced risk of all-cause mortality, with the survival benefit being more pronounced in patients under 65 years of age and those with cardiometabolic comorbidities.

If you have obesity or type 2 diabetes, starting a GLP-1 RA (like semaglutide or liraglutide) is strongly associated with living longer, especially if you are under 65 or have other heart/kidney risks. While there is a small, early risk of pancreatitis, the survival benefit is substantial. Discuss this risk-benefit profile with your doctor, particularly if you have a history of pancreatic issues.

GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) cause a significant reduction in skeletal muscle mass (30-40% of total weight loss), posing a risk for sarcopenia, particularly in elderly patients and those with type 2 diabetes.

If you are taking semaglutide or tirzepatide, expect to lose some muscle along with fat. To protect your strength, you must eat more protein (at least 1.2g/kg/day) and perform resistance training 2-3 times per week. This is especially critical if you are older or already have low muscle mass.

GLP-1 receptor agonists lower blood pressure through central sympathetic inhibition, natriuresis, and improved endothelial function, with effects largely independent of weight loss.

GLP-1 drugs (like Ozempic or Wegovy) lower blood pressure through multiple pathways: they calm the nervous system's stress response, help kidneys excrete salt, and improve blood vessel health. This happens even before significant weight loss occurs.

MC4R agonists significantly reduce triglyceride and LDL-C levels, and lower systolic blood pressure, but have no significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure.

MC4R agonists not only help you lose weight but also significantly improve your lipid profile by lowering triglycerides and LDL cholesterol, and they can lower systolic blood pressure. However, they do not appear to have a significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure. These metabolic benefits make them a valuable treatment for reducing overall cardiovascular risk in patients with obesity.

Higher doses of orforglipron (36-45 mg) are associated with increased treatment discontinuation due to adverse events compared to lower doses and placebo.

Higher doses of orforglipron work better for weight loss but cause more side effects, leading some people to stop taking it. If you struggle with side effects, ask your doctor about a lower dose (24-36 mg) which may be easier to tolerate.

Orforglipron 36 mg is the optimal dose for improving lipid profiles (triglycerides, total cholesterol) and blood pressure while maintaining better tolerability than 45 mg.

If your main goal is improving cholesterol and blood pressure rather than maximum weight loss, the 36 mg dose of orforglipron offers a good balance of efficacy and tolerability.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly in obese individuals undergoing rapid weight loss, though the risk for pancreatitis is not consistently supported by recent large-scale data.

Be aware that GLP-1 medications slightly increase the risk of gallbladder issues, especially if you lose weight quickly. However, recent data suggests the risk of pancreatitis is not significantly higher than with other treatments. Discuss your personal risk factors with your doctor, who may recommend monitoring.

Early rapid weight loss (≥15% by Week 24) with incretin-based obesity medications (tirzepatide or semaglutide) predicts greater overall efficacy (higher probability of achieving ≥25-30% total weight loss) without negatively impacting study completion rates, despite a numerically higher incidence of gastrointestinal and hepatobiliary adverse events.

If you are starting tirzepatide or semaglutide, losing weight quickly in the first few months is a good sign that you will likely achieve your long-term weight loss goals. While you may experience more stomach issues early on, this does not mean you will quit treatment. Monitor your health, manage side effects as needed, and trust that early rapid response is a positive predictor of success.

Flexible, gradual titration of GLP-1 receptor agonists significantly reduces nausea and vomiting rates and discontinuation compared to standard rapid titration without compromising weight loss efficacy.

When starting a GLP-1 medication like semaglutide, do not rush to the highest dose. Start at the lowest possible dose and increase it slowly. If you feel mild nausea, pause the dose increase until it passes. If you vomit or feel significantly unwell, go back to the last dose that felt okay. This 'start low and go slow' approach prevents side effects and keeps you on the medication long enough to lose weight, which is the actual goal. You do not need to reach the maximum dose to get benefits; your body's tolerance is your guide.

Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.

Tirzepatide is a once-weekly injection for diabetes and obesity that also shows strong promise for treating MASH. It reduces liver fat and inflammation significantly, with higher doses showing better results. It also leads to greater weight loss than Semaglutide in head-to-head comparisons.

Bariatric surgery (gastric banding, bypass, sleeve gastrectomy) results in large weight loss, induces remission of type-2 diabetes and hypertension, and increases life expectancy.

For severe obesity where other methods fail, bariatric surgery is a highly effective option that can lead to significant weight loss and remission of conditions like diabetes and high blood pressure. It can also increase life expectancy and be cost-effective over the long term, provided resources are available.

Preoperative Total Abdominal Fat Area (TAFA) is an independent predictor of excellent weight loss outcomes following laparoscopic sleeve gastrectomy, with lower TAFA predicting higher likelihood of achieving >75% excess weight loss and >30% total weight loss.

If you are considering sleeve gastrectomy, ask your surgeon about measuring your abdominal fat area (via CT or MRI) before surgery. A lower abdominal fat area is associated with a significantly higher chance of achieving excellent weight loss results. This metric offers more predictive power than BMI alone.

Semaglutide improves cardiovascular risk factors, including blood pressure and heart failure symptoms, in patients with obesity.

Semaglutide may help lower blood pressure and improve heart function in obese patients with heart failure, in addition to aiding weight loss.

Insomnia and insufficient sleep duration are independent cardiovascular risk factors that should be addressed alongside OSA.

If you have sleep apnea but also struggle with insomnia or don't get enough sleep, treating those issues is just as important for your heart as using your CPAP. Ask your doctor about Cognitive Behavioral Therapy for Insomnia (CBTi), which is the gold standard treatment for insomnia.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) induce weight loss by delaying gastric emptying and increasing satiety, but long-term cost-effectiveness modeling is hindered by uncertainty regarding sustained BMI trajectories and weight regain upon cessation.

GLP-1 medications like semaglutide and tirzepatide work by slowing digestion and reducing hunger, leading to significant weight loss. However, these drugs are not a one-time cure. Stopping treatment typically leads to weight regain, suggesting that obesity management with these agents is likely a long-term commitment. Cost-effectiveness models struggle to predict long-term outcomes because clinical trials are short, making it difficult to know if the weight loss will be sustained indefinitely.

Ultra-processed food (UPF) consumption drives overconsumption and weight gain independently of macronutrient composition, energy density, or fiber content, primarily by hijacking brain reward systems and creating neurological addiction.

Stop blaming yourself for lack of willpower. Your brain's reward system is likely hijacked by ultra-processed foods, making it biologically difficult to stop eating. Focus on eliminating UPFs entirely (abstinence) rather than trying to moderate them, as this addresses the root neurological cause of overconsumption.